...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Reply from Sarah

I think Sarah has said what I have been trying to, but I have just carried it further. I will say again that I think you are getting ahead of yourself. This proposal is just a first step.

Sarah said "Current shareholders' shareholdings will not change (other than the name of the company, as mentioned" which does answer one of your questions. IMO the valuation means nothing to you as a shareholder. Sarah also said the valuation "is not really comparble to the $1 per share". It is an internal reorganization not a split.

We are all tired of waiting but Zenith is moving towards something really good...JMHO.

PVLee

Share
New Message
Please login to post a reply